|Day Low/High||195.28 / 198.51|
|52 Wk Low/High||163.31 / 201.23|
Big pharma firm looks good overall, but is falling with the rest of Wall Street.
In the August Action Alerts PLUS members' call, Jim Cramer and Jeff Marks, Senior Portfolio Analyst of Action Alerts PLUS, discuss the portfolio's new edition of Amgen.
The Dow Jones Industrial Average declined by 125 points on Monday.
It is all about perception, and here are strong names to pick up on market weakness.
The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
For those looking for the key takeaway of the call, herewith the 11 investing lessons we discussed.
We are adding to our Amgen position into today's weakness and financing it by reducing our PayPal holdings.
We left ourselves plenty of room to take advantage of a down day like this.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
We initiated a new position, raised a price target after earnings and upgraded the rating on another holding.
Markets edged higher in what was a busy week from both a political and economic perspective.
Jim discusses earnings for DowDuPont and WestRock, our Amgen initiation, UnitedHealth Group, Kohl's, BP, Apple and more!
We have kept a healthy cash position to take advantage of down days like this.
We are bringing AMGN out of the Bullpen and into the portfolio.
The Plant Will be First-of-its-Kind in the U.S.
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.
We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.
Here are 3 ways to play these 3 stocks on earnings.
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today.
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018.
U.S. stock futures are mixed as investors react with caution to a broadly worded trade truce between the European Union and the United States; Facebook tanks as the social media giant points to slower growth; AMD swings to a profit; Qualcomm scraps deal for NXP.
THOUSAND OAKS, Calif., July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the U.
First Amgen Collaboration With Academic Medical Center Focused on Research, Health Service Redesign and Outcomes-Based Care
New Resources Available at MyelomaExplained.com Help Patients Set Goals and Prepare for Discussion With Doctor to Create Individualized Treatment Plan
BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.